Crinetics Pharmaceuticals Inc Q2 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Fye - JPMorgan - Analyst : Good afternoon. Thanks for taking my question. Marc, it's been great working with you over the years. I was wondering how we should think about what additional insights we could expect to gain from the Phase 2 updates in CAH and Cushing's coming later this year. And what venue or venues we should look for those at?

Question: Yasmeen Rahimi - Piper Sandler - Analyst : Marc, we're going to greatly miss you. It's been really a pleasure working with you and we have done a tremendous job. So, we will definitely miss you and hope the search continues for a little longer so we can continue working with you. Wanted to ask just a question on carcinoid. If you could provide some color around engagement with the agency. Where are you in terms of the sign off? And what's sort of left to do to kick off the registrational study and I'll jump back into the queue.

Question: Jeff Hung - Morgan Stanley - Analyst : Thank you for taking my question, and best wishes to Marc. You mentioned that you may advance your ADPKD program with a partner independently. What would be the deciding factors for Crinetics to go with one strategy versus the other? And is that the only, is that only relevant to this program, or are there specific early-stage programs that you would not be opening open to partnering? Thanks.

Question: Dennis dean - Jefferies - Analyst : Thanks for taking my question. Maybe if I can ask one on Atumelnant, here how you're thinking about the pricing strategy once you guys eventually get approved next year if you plan a price at a premium given. Thank you so much.

Question: Joseph Schwartz - Leerink Partners - Analyst : Thanks, very much. Best wishes to Marc, of course, that's been great to work with you. Are specific clinical outcomes being systematically measured in Tucan, or was the observation of two patients who resumed menstruation? Something that was just noticed. I'm just wondering if there are other clinical benefits that might arise when you report top-line data in the second half.

Question: Joseph Schwartz - Leerink Partners - Analyst : Very helpful. Thanks, Alan.

Question: Gavin Clark Gardiner - Evercore ISI - Analyst : Thank for taking my question. I just wanted to ask more specifically on the carcinoid regulatory feedback as we're getting close to that. What's your desired base case or expectation on primary endpoint confidence that a placebo comparator arm will be viable? And also, just reconfirm you're looking at both switch and new starts and confirming those would be within the same one trial. Thank you.

Question: Gavin Clark Gardiner - Evercore ISI - Analyst : It's just reconfirming whether placebo or an active compared to arm maybe required.

Question: Charles Moore - Baird - Analyst : This is Charlie on for Brian. Thanks for taking our question. So just thinking about the profile of paltusitine we've seen so far, do you have any plans to investigate it in the treatment of neuroendocrine tumors in the future?

Question: Charles Moore - Baird - Analyst : Thank you.

Question: Catherine Novak - Jones Research - Analyst : Hey, good afternoon, guys. If I can just one about the pipeline again. I'm curious about the role of SST3 agonism in ADPKD. If you can just talk about your decision to go into ADPKD and how this approach might differentiate from earlier studies that looked at anti-proliferative drugs, which seemed to reduce kidney volume, but not necessarily improve kidney function per se.

Question: Catherine Novak - Jones Research - Analyst : Well, thanks that definitely looking forward to hearing more from that program in the future.

Question: Jon Wolleben - Citizens JMP - Analyst : Best wishes to Marc. Was hoping you guys could talk a little bit about how you're thinking about next steps, specifically in CAH? if you think you'd have enough information to move forward to a Pivotal trial, and then how you're thinking about integrating younger patients into the program as well?

Question: Jon Wolleben - Citizens JMP - Analyst : Thank you very much.

Question: Leland Gershell - Oppenheimer - Analyst : Good afternoon. Thanks for taking my question. Marc, it has been great working with you and best of luck in the future. Scott, wanted to ask on your thyrotropin receptor program, you'd mentioned recent calls that you've been moving nicely along with potential candidates. Just wondering where you may be there? Could we see a clinical candidate nominated in the next few months or perhaps in 2025?

Question: Leland Gershell - Oppenheimer - Analyst : Great, Thanks.

Question: Douglas Tsao - H.C. Wainwright - Analyst : I'll join the chorus of people saying how much we've enjoyed working with Marc over the years. I guess maybe a question for Jim, since he mentioned the fact that patients often have a very different experience with acromegaly than clinicians realize. So, I guess in terms of driving adoption how do you plan to get around that? Because I think that has been a factor that has hampered. There was the launch of CAH so in terms of converting that product. And I know that this profile is very different. You have much, much stronger data, but just how do you from a tactical standpoint, plan to address that aspect of the launch? Thank you.

Question: Douglas Tsao - H.C. Wainwright - Analyst : Okay, great. Thank you so much and that's helpful.

Question: Cory Jubinville - LifeSci Capital - Analyst : Congrats on all the progress. Marc congrats on everything you've helped build over the years. Will definitely be sad to see you go, but of course, wish you well and whatever comes next. But I guess can you help give us a bit of context in how your launch efforts in acromegaly could potentially help support a launch in carcinoid syndrome down the line? Thinking about these prescriber groups as almost like a Venn diagram, how might a carcinoid patient, how often might a carcinoid patient be coming in contact with an endocrinologist that might have had previous experience with paltusitine treating acromegaly? While it's certainly been several years ago, are there any learnings you're taking from the expansion of octreotide or lanreotide into these patient groups from acromegaly to carcinoid syndrome or get net that that can be applied to your strategy with paltusitine?

Question: Cory Jubinville - LifeSci Capital - Analyst : Thank you.